Technical Analysis for BRTX - Biorestorative Therapies Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | N/A | Up |
Historical BRTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Spinning Top | Other | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Upper Bollinger Band Walk | Strength | -3.03% | |
Wide Bands | Range Expansion | -3.03% | |
Upper Bollinger Band Touch | Strength | -3.03% | |
Upper Bollinger Band Walk | Strength | -12.73% | |
Wide Bands | Range Expansion | -12.73% |
Get this analysis on your stocks daily!
Biorestorative Therapies Inc Description
BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition
Classification
Sector: Other
Industry: Other
Keywords: Biotechnology Biology Life Sciences Surgery Pain Stem Cells Cell Biology Therapeutic Product Cell Therapy Spine Food And Drug Administration Obesity Therapeutic Products Endocrine System Skeletal System Bone Marrow Back Pain Pfizer Metabolic Disorders Adult Stem Cell Adipose Tissue Mesenchymal Stem Cell Rtx Invasive Procedure Invasive Procedures Surgical Treatment Therapeutic Brtx 100to Curved Needle Device Disc/Spine Disease Investigational Curved Needle Device Non Surgical Treatment Painful Lumbosacral Disc Disorders Rohto Pharmaceutical The University Of Pennsylvania Tissue Protocols Treatment Of Disc/Spine Disease Treatment Of Painful Lumbosacral Disc Disorders University Of Pennsylvania
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.0331 |
52 Week Low | 0.0047 |
Average Volume | 49,422,643 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.0000 |
20-Day Moving Average | 0.0084 |
10-Day Moving Average | 0.0095 |
Average True Range | 0.0025 |
ADX | 27.01 |
+DI | 29.2754 |
-DI | 15.6522 |
Chandelier Exit (Long, 3 ATRs ) | 0.0105 |
Chandelier Exit (Short, 3 ATRs ) | 0.0122 |
Upper Bollinger Band | 0.0118 |
Lower Bollinger Band | 0.0050 |
Percent B (%b) | 0.68 |
BandWidth | 80.9524 |
MACD Line | -0.0002 |
MACD Signal Line | -0.0007 |
MACD Histogram | 0.0005 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0113 | ||||
Resistance 3 (R3) | 0.0113 | 0.0107 | 0.0110 | ||
Resistance 2 (R2) | 0.0107 | 0.0103 | 0.0107 | 0.0109 | |
Resistance 1 (R1) | 0.0102 | 0.0101 | 0.0105 | 0.0102 | 0.0108 |
Pivot Point | 0.0096 | 0.0096 | 0.0098 | 0.0096 | 0.0096 |
Support 1 (S1) | 0.0091 | 0.0092 | 0.0094 | 0.0091 | 0.0084 |
Support 2 (S2) | 0.0085 | 0.0090 | 0.0085 | 0.0083 | |
Support 3 (S3) | 0.0080 | 0.0085 | 0.0082 | ||
Support 4 (S4) | 0.0080 |